Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Inks Deal with Investment Bank for Potential Share Sale

NEW YORK (GenomeWeb News) – Complete Genomics today announced an agreement with investment bank MLV & Co. for the potential sale of an aggregate of $30 million of its common stock.

The sale of Complete Genomics' stock would be made on the Nasdaq Global Market under the Mountain View, Calif.-based firm's currently effective Form S-3 at market prices. Shares also may be sold through MLV at negotiated prices or at prices related to the prevailing market price, Complete Genomics said.

Last week, the company announced that its fourth-quarter revenues had dropped 34 percent year over year. It ended 2011 with $83.1 million in cash, cash equivalents, and short-term investments, plus $500,000 in restricted cash. A company official said cash on hand would take it through the end of the year, leading several analysts to say that a cash raise, particularly in the second half of the year, would be expected.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.